Personal information

No personal information available

Biography

PROFESSIONAL ACTIVITY
Collaborates as a consultant with Pharmaceutical Companies, with Investment Funds and with Research Organisations, focusing his activity in the areas of Research and Development, including clinical development. He has collaborated with many Pharmaceutical Companies, presently he is Managing Director of Rare Partners, a non profit company located in Milano, devoted to development of drugs and of diagnostics for rare diseases. The company has been founded in March 2010 with the aim of covering the gap now existing between basic research results and their application in the clinical setting (www.rarepartners.org).

RELEVANT PREVIOUS EXPERIENCE
2013 -2016: Prismic Pharmaceuticals (Scottsdale, Arizona), where he collaborated as a consultant in the projects related to chronic kidney disease and pain. His responsibility has been to collaborate as a senior scientific advisor on the design and organization of preclinical and clinical work.

2009-2010: BioPharmaNet, a network of academic and industrial laboratories, located in the Emilia-Romagna region (Italy), active in research and innovation for industry in the field of Life Sciences, where he was Marketing Manager

2006-2010 ReDD srl (Roma), spin-off of the University of Roma Tor Vergata devoted to discovery and early development in the field of biomedical products, where he was scientific leader of a project for new companies development funded by the Italian Ministry of Scientific Research

2005-2009: PharmEste, srl (Ferrara), spin-off of the University of Ferrara devoted to drug discovery and development in the field of TPRV receptors, where he has covered several roles, including the position of R&D Director

2003-2005: Trastec scpa, (previously named Padova Ricerche), a non profit organisation whose main owner was the University of Padova, active in the field of research management and education, working in many cases with companies and public institutions, where he has been general director

1996-2004: Angelini Ricerche (Pomezia- Roma), where he collaborated in the activities of pharmacological laboratories in the area of pre-clinical pharmacological and toxicological R&D, mainly involved in Pain and Inflammation research.

1999-2002: Scientific Park Galileo Galilei (Padova), where he has been in charge of a project named SIL (Integrated System of Laboratories) with the aim to integrate several University and private Laboratories, upgrading their capability and obtaining accreditation for specific tests in different areas, in order to provide optimal service to local industries.

1996-2002: Tecnofarmaci (Pomezia- Roma), where he co-ordinated the preparation of grant proposals involving Pharmaceutical Companies and academic researchers.

1992-1996: Director of Research in Fidia Research Laboratories.

1990-1992: Director of Pre-Clinical and Clinical Pharmacological Research in Fidia Research Laboratories.

1981-1990: Head of Cardiovascular Research Group in Fidia Research Laboratories

1979-1980: Research Associate at the Department of Pharmacology, Jefferson Medical College, Philadelphia

1973-81: Research fellow at the University of Padova, Institute of Pharmacology

ACTIVITIES PERFORMED IN THE PAST AND IN THE PRESENT POSITION
• Scientific Research in the fields of cardiovascular pharmacology, autonomic innervations and inflammation/pain
• Meetings with Regulatory Authorities at national and international level (CPMP, EMA)
• Management of a company including the preparation of the financial reports, of the documents for the Board and of the relationships with the internal and external auditors
• Management of internal Research Groups and of research projects in collaboration with academic groups at international level. Preparation of budget, forecast and final reports of expenses
• Management of relationships with CROs in the fields of toxicology, ADME, pharmacology and clinical research
• Preliminary contacts for licensing-in and licensing-out of drugs and drug candidates
• Preparation of patent applications and documents related to patent litigation
• Preparation of grant applications and of final reports for activities related to R&D, to continuing education and to industrial reconversion
• Organisation of meeting on local, national and international level
• Knowledge of the rules and bodies involved in the process of laboratory accreditation and product certification


RESEARCH ACTIVITIES
Member of several Scientific Societies and author of more than 120 papers, 200 abstracts and several patents, on cardiovascular and autonomic pharmacology, both at preclinical and clinical level

SPECIFIC EXPERIENCE IN SECURING COMPETITIVE FUNDING
As Managing Director of Rare Partners, he has been awarded competitive grants by the Wellcome Trust (Pathfinder Award, Innovator Award), by the Eurotransbio Project, by Regione Lombardia and by Milan Chamber of Commerce.

Activities

Employment (1)

Rare Partners srl Impresa Sociale: Milano, IT

2010-03-25 to present | Managing Director
Employment
Source: Self-asserted source
Marco Prosdocimi

Education and qualifications (1)

University of Padova: Padova, IT

1969-11-01 to 1973-07-13 | Doctor
Education
Source: Self-asserted source
Marco Prosdocimi

Funding (1)

A personalised medicine approach for beta-thalassemia patients: testing sirolimus in a first pilot clinical trial (Sirthalaclin

Works (9)

Decrease in α-Globin and Increase in the Autophagy-Activating Kinase ULK1 mRNA in Erythroid Precursors from β-Thalassemia Patients Treated with Sirolimus

International Journal of Molecular Sciences
2023-10-10 | Journal article
Contributors: Matteo Zurlo; Cristina Zuccato; Lucia Carmela Cosenza; Jessica Gasparello; Maria Rita Gamberini; Alice Stievano; Monica Fortini; Marco Prosdocimi; Alessia Finotti; Roberto Gambari
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Decrease of α-Globin and Increase of the Autophagy-Activating Kinase ULK1 mRNA in Erythroid Precursors from β-Thalassemia Patients Treated with Sirolimus

2023-09-04 | Preprint
Contributors: Matteo Zurlo; Cristina Zuccato; Lucia Carmela Cosenza; Jessica Gasparello; Maria Rita Gamberini; Alice Stievano; Monica Fortini; Marco Prosdocimi; Alessia Finotti; Roberto Gambari
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

The Long Scientific Journey of Sirolimus (Rapamycin): From the Soil of Easter Island (Rapa Nui) to Applied Research and Clinical Trials on β-Thalassemia and Other Hemoglobinopathies

Biology
2023-09-02 | Journal article
Contributors: Roberto Gambari; Cristina Zuccato; Lucia Carmela Cosenza; Matteo Zurlo; Jessica Gasparello; Alessia Finotti; Maria Rita Gamberini; Marco Prosdocimi
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

β-sitosterol ameliorates inflammation and Pseudomonas aeruginosa lung infection in a mouse model

Journal of Cystic Fibrosis
2023-01 | Journal article
Contributors: Alice Rossi; Alessandra Bragonzi; Melessike Medede; Ida De Fino; Giuseppe Lippi; Marco Prosdocimi; Anna Tamanini; Giulio Cabrini; Maria Cristina Dechecchi
Source: check_circle
Crossref

A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs [version 3; peer review: 2 approved]

2022-08-17 | Journal article
Part of ISSN: 2398-502X
Funded by GRANT_NUMBER:

208872/Z/17/Z

Funded by GRANT_NUMBER:

306201

Funded by GRANT_NUMBER: AIFA-2016-02364887
Contributors: Marco Prosdocimi; Cristina Zuccato; Lucia Carmela Cosenza; Monica Borgatti; Ilaria Lampronti; Alessia Finotti; Roberto Gambari; Borgatti Monica; Cosenza Lucia Carmela; Cosenza Lucia Carmela et al.
Source: check_circle
Wellcome Open Research
grade
Preferred source (of 2)‎

A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs

Wellcome Open Research
2022-06-23 | Journal article
Contributors: Marco Prosdocimi; Cristina Zuccato; Lucia Carmela Cosenza; Monica Borgatti; Ilaria Lampronti; Alessia Finotti; Roberto Gambari
Source: check_circle
Crossref

A Rational Approach to Drug Repositioning in β-thalassemia: Induction of Fetal Hemoglobin by Established Drugs

Wellcome Open Research
2022-05-12 | Journal article
Contributors: Marco Prosdocimi; Cristina Zuccato; Lucia Carmela Cosenza; Monica Borgatti; Ilaria Lampronti; Alessia Finotti; Roberto Gambari
Source: check_circle
Crossref

Sirolimus for Treatment of β-Thalassemia: From Pre-Clinical Studies to the Design of Clinical Trials

Health Education and Public Health
2021 | Journal article
Part of ISSN: 2631-8377
Source: Self-asserted source
Marco Prosdocimi

Expression of γ-globin genes in β-thalassemia patients treated with sirolimus: results from a pilot clinical trial (Sirthalaclin)

[]
2021-12-21 | Preprint
Source: Self-asserted source
Marco Prosdocimi